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Introduction: Rheumatoid arthritis (RA) is a chronic disease, affecting 0.5 to 1% of adults in industrialized countries,
in which systemic inflammation and synovitis drive joint destruction. [18F]DPA-714 is a specific tracer of the 18 kDa
translocator protein (TSPO), which is overexpressed on activated macrophages, and proposed as a biomarker of
neuroinflammation. Today, diagnosis of patients with early inflammatory arthritis is limited by poor sensitivity and
specificity. The present study aims to investigate the potential of [18F]DPA-714 to monitor in vivo inflammatory
processes at a preclinical stage via positron emission tomography (PET).
Methods: RA was induced in Dark Agouti rats by subcutaneous injection of inactivated Mycobacterium tuberculosis.
Development of arthritis clinical signs was investigated daily and the severity of the disease evaluated. Animals
were imaged at the peak of inflammation using [18F]DPA-714 and a small-animal PET-CT tomograph.
Results: The first clinical signs appeared at 10 days post-injection, with a peak of inflammation at 20 days. At this
time, PET-analyses showed a clear uptake of [18F]DPA-714 in swollen ankles, with mean values of 0.52 ± 0.18%
injected dose (ID/cc) for treated (n = 11) and 0.19 ± 0.09 for non-treated (n = 6) rats. A good correlation between
[18F]DPA-714’s uptake and swelling was also found. Immunohistochemistry showed an enhanced TSPO expression
in hind paws, mainly co-localized with the macrophages specific antigen CD68 expressing cells.
Conclusion: These preliminary results demonstrate that the TSPO 18kDa specific radioligand [18F]DPA-714 is
adapted for the study and follow-up of inflammation linked to RA in our experimental model, suggesting also a
strong potential for clinical imaging of peripheral inflammation.Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
order that can affect many tissues and organs. This dis-
ease leads to progressive joint destruction principally
due to synovial inflammation, but also to articular com-
plications and functional disability. In addition to caus-
ing joint problems, RA can also affect the whole body
with fevers and fatigue. RA is a systemic autoimmune
disease that also leads to many disorders in organ sys-
tems and is associated with other diseases, including in-
fections, malignancies and cardiovascular diseases. One
percent of the world's population today is affected by* Correspondence: raphael.boisgard@cea.fr
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reproduction in any medium, provided the orRA with a repartition much more common in women
than in men with ages ranging from 40 to 60 years [1].
Smoking is the main environmental risk factor for devel-
oping RA. Other potential risks, including alcohol abuse,
vitamin D status, contraception use and coffee intake,
have been reported too [2].
The detection of RA is important in clinical strategies
that include early treatments which may slow down the
disease progression and improve the long-term clinical
outcome. Criteria proposed in 1987 by the American
College of Rheumatology (ACR) 1987 are rather limited
by the poor sensitivity and specificity for the classifica-
tion of patients with early RA [3]. These criteria include
morning stiffness, arthritis of three or more areas, arth-
ritis of hand joints (>1 swollen joint), rheumatoid nod-
ules, serum rheumatoid factor, radiographic changes
(erosions). However, early events failed to be detected byLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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in RA is traditionally the domain of plain radiography.
In parallel to this, other techniques such as Magnetic
Resonance Imaging and Ultrasound have demonstrated
a superior sensitivity for the detection of erosive changes
around the bone. Several teams have shown that sub-
clinical arthritis can be detected by advanced imaging
techniques such as sonography or power Doppler [4-6].
The development of non-invasive, highly sensitive and
3D-imaging-based methods for detecting early arthritis
could also offer an opportunity to initiate treatments at
very early stages to the patient.
Molecular- and nuclear-based imaging techniques offer a
large scale opportunity for detection of diseases. These
techniques are based on the use of tracers labeled with
radioactive isotopes and allow non-invasive in vivo detec-
tion of different physiologic and pathologic phenomena
with high sensitivity. Positron Emission Tomography (PET)
is one of those that are increasingly used to diagnose and
characterize disease activity in the setting of inflammatory
disorders such as RA [7-10]. PET is even more sensitive
than Single Photon Emission Computed Tomography
(SPECT) and can also provide quantitative measurements.
The low spatial resolution can make assigning the signal to
specific anatomical structures difficult and can be partially
compensated by combining PET with CT (X-ray Computed
Tomography). [18F]Fluorodeoxyglucose ([18F]FDG), a radio-
fluorinated analogue of glucose and the most widely used
radiopharmaceutical worldwide today, was proposed for
imaging RA [11,12]. Using this radiotracer, inflamed joints
could be detected even though [18F]FDG is not a specific
marker of inflammation. Macrophage infiltration has been
identified in early stages of RA [13], and therefore a spe-
cific tracer of such a process would be more specific and
possibly also enable an earlier detection of inflammation.
Recently, expression of the folate receptor has been inves-
tigated in a rat model of RA using [18F]fluoro-PEG-folate
[14] illustrating the interest for molecular imaging in this
type of pathology.
The 18kDa translocator protein (TSPO), previously
known as the peripheral benzodiazepine receptor (PBR), is
located in the outer mitochondrial membrane [15]. This
protein is up-regulated in inflammatory processes, making
radiolabeled TSPO ligands attractive imaging probes in a
multitude of pathologies. Different TSPO ligands have
already been used as imaging probes in different animal
models of human diseases such as cancer [16], cerebral is-
chemia [17], lung [18] and liver diseases [19].
Today, [11C]PK11195 is still considered as the reference
radioligand for imaging in vivo TSPO expression mainly
in central nervous system disorders and rarely in the case
of peripheral inflammatory diseases. Numerous publica-
tions in the recent literature have, however, highlighted
the limitations of this radiotracer for quantitative in vivomeasurement of TSPO expression [20] and several novel
TSPO radioligands have been developed today as alterna-
tives to the use of [11C]PK11195 [21-23]. Among them,
the pyrazolo [1,5] pyrimidine acetamide DPA-714, labeled
with fluorine-18 ([18F]DPA-714) is one of the most prom-
ising compounds. For the moment, [18F]DPA-714 is
mainly used to image brain injury in various animal
models [17,24-26] but also in the field of oncology with
applications in breast cancer [27] and glioma [28]. Interest
for the molecular imaging of peripheral inflammation has
also been investigated recently in non-alcoholic fatty liver
disease in rats [19] and lungs by the same team [18] using
another radiolabelled TSPO ligand ([18F]FEDAC). Re-
cently, [11C]PK11195 has been shown to be of potential
interest in imaging arthritis in humans [7,10,29]. The
visualization of macrophages using [11C]PK11195 PET
seems to be useful for detecting early synovitis and for
monitoring disease evolution during treatment.
The present study aims to investigate the potential of
[18F]DPA-714 PET to image and quantify in vivo periph-
eral inflammation in an autoimmune adjuvant-induced
RA rat model.Methods
Animals
Male Dark Agouti rats (216.7 g ± 16.4 g) were purchased
from Centre d’Elevage René Janvier (Saint Berthevin,
France), housed and acclimatized for one week before treat-
ment with free access to food and water. Animal studies
were conducted in accordance with the French legislation
and European directives (2010/63/UE) on the uses of ani-
mals in research. Experiments were done in the approved
French laboratory D 91 471 105 from 2 August 2012, under
the supervision of the institutional ethical committee
(CETEA DSV, recorded in 6 June 2011 under No. 44 by
CNREEA, National Committee for ethical reflection on
animal experimentation).Preparation of CFA (complete Freund’s adjuvant)
Mycobacterium tuberculosis H37 Ra (Mtb) and incomplete
Freund’s adjuvant (IFA) were purchased from Difco La-
boratories (USA). CFA was prepared as follows: IFA
(20 mL) was drop-wise added, with continuous mixing, to
finely crushed Mtb (100 mg). The resulting oily prepar-
ation (Mtb: 5 mg/mL) may be temporarily stored at -20°C
if not readily used.Induction of RA
Rats were anesthetized with an isoflurane/oxygen mix-
ture (2 to 4%). Induction of RA was performed for each
rat by intra-dermal injection at the base of the tail of
100 μL (single dose) of the above reported CFA.
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Rats were observed daily. Animals were weighed and de-
velopment of arthritis clinical signs investigated every
two days. The clinical severity of RA was evaluated ac-
cording to the following scale: 1 = detectable swelling in
one joint; 2 = swelling in two joints; 3 = swelling in three
joints; 4 = severe swelling of the entire paw. The max-
imum score per animal for the four paws was 16. Each
observation was done under short anesthesia using an
isoflurane/oxygen mixture (2 to 3%).
[18F]DPA-714 preparation
DPA-714 was labeled with fluorine-18 (half-life, 109.8
minutes) at its 2-fluoroethylmoiety using a tosyloxy-for-
fluorine nucleophilic aliphatic substitution, according to
slight modifications of procedures already reported [30,31],
and using a commercially available GE TRACERLab FX-
FN synthesizer [32]. Ready-to-inject, >99% radiochemically
pure [18F]DPA-714 (formulated in physiological saline con-
taining less than 10% of ethanol) was obtained with 15 to
20% non-decay-corrected yields and specific radioactivities
at the end of the radiosynthesis ranging from 37 to
111 GBq/μmol. Injected doses (MBq and nmoles, mean ±
SD) will be given within the text.
PET/CT imaging and data analysis
PET/CT scans were performed using small-animal
INVEON (Siemens, Munich, Germany) tomography. This
system combines both PET and CT modalities under the
control of a unique workstation, including CT-based at-
tenuation correction which allows for superior quality
PET images. PET/CT scans were performed around the
peak of the disease (20 days) following CFA-injection in
all animals showing a clinical score ranging from 1 to 16
as well as in control animals (free of injection).
Animals were anesthetized with an isoflurane/oxygen
mixture (2 to 4%) and maintained normothermically using
a heating pad. Injections of [18F]DPA-714 were made in
the caudal lateral vein using a 24-gauge catheter.
Dynamic acquisitions were done as follows: im-
aging started at the time of injection of [18F]DPA-714
(38.0 +/ -3.1 MBq/rat corresponding to 2.2 +/ -0.8 nmol
by injection) and continued for 60 minutes (n = 5).
Static acquisitions were obtained 45 minutes after injec-
tion of the radiotracer and lasted for a period of 15 mi-
nutes (n = 6). In displacement studies (n = 3) animals
received, 30 minutes post [18F]DPA-714-injection, a so-
lution of DPA-714 (5 mg/kg) intravenously. Data acqui-
sition was continued for another 30 minutes.
All PET-measurements were performed with a time co-
incidence window of 3.432 ns and the energy levels of dis-
crimination at 350 keV and 650 keV. The list mode data
files were histogrammed into 3D-sinograms with a max-
imum ring difference of 79 and a span of 3. Images werereconstructed using ASIPro (Siemens) with the FORE +
OSEM2D algorithm (16 subsets and 4 iterations).
Image analysis and quantification of radioactivity in
volumes of interest were performed using Brain-Visa/
Anatomist version 3.1 [33]. Regions of interest (ROIs)
were drawn on the ankle joints. These ROIs were then
projected onto all dynamic frames, thereby creating time
activity curves for each ROI. Radioactivity uptake values
were quantified in Bq per cubic cm (cc) of tissue, cor-
rected for fluorine-18-decay and converted into the per-
centage of injected dose per cubic cm (% ID/cc).Histology
After rat euthanasia (lethal dose of pentobarbital 150 mg/
kg), the paws were then collected and fixed in 10% (v/v)
buffered formalin phosphate (Labonord, France) for 24 h
to 48 h, before being decalcified using Immunocal (Decal
Chemical Corporation, USA) for two weeks. After decalci-
fication, the paws were frozen in liquid nitrogen and
stored at -80°C before being sliced with a cryotome (Leica
CM3050, Germany). Finally, the ankle joints were cut in a
sagittal plane and sectioned at 5 μm.
Selected sections were stained with Mayer’s hematoxylin
solution (Sigma, USA) and eosin-y (Labonord, France) or
directly used for immunohistochemistry.Immunohistochemistry
Immunohistochemistry (IHC) was performed on 5 μm
frozen sections of paw slices. Slices were placed for 15 mi-
nutes in fixative containing 4% paraformaldehyde in PBS
(phosphate-buffered saline), then removed and placed in
50 mM aq. NH4Cl for 5 minutes. Slices were then placed
in PBS containing 5% BSA (bovine serum albumin)
(Merck, Germany) and 0.5% Tween 20 (Sigma, USA) for
five minutes at room temperature (RT). Finally, slices were
incubated (1 h, RT) with the following primary antibodies
in solution in the above mentioned buffer: mouse anti-
CD68 (MRA341R, 1:100; Serotec, Germany), goat anti-Iba
1 (ab5076, 1:100; Abcam, UK) and rabbit anti-TSPO
(NBP1-95674, 1:1,000; Novus Biologicals, UK).
Slices were then washed three times with PBS and then
incubated (30 minutes, RT) with Alexa Fluor-546 donkey
anti-mouse (A10036, 1:1,000; Invitrogen, France), Alexa
Fluor-647 donkey anti goat (A21447, 1:1,000; Invitrogen,
France), Alexa Fluor-488 goat anti-rabbit (A11034; 1:1,000;
Invitrogen, France), respectively, in a solution of PBS con-
taining 5% BSA and 0.5% Tween 20.
Slices were again washed three times in PBS and then
mounted with a DAPI Kit (P36931 Invitrogen, France).
The number of CD68-, TSPO- and Iba1-positive cells
were counted under the ×20-objective of an Axio obser-
ver Z1 microscope (Zeiss, France) on seven fields of
view taken from three adjacent sections per rat.
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Statistical analyses were conducted using Microsoft Excel
software. A significant difference between arthritic and con-
trol groups was determined at each point by the one-tailed




An arthritic model was induced by a single dose injec-
tion of 0.5 mg of Mycobacterium tuberculosis H37 Ra
(Mtb) in male Dark Agouti rats (DA rats). During the
disease progression, two parameters were followed: the
bodyweight and the joint swelling. These parameters are
both reported as systemic RA symptoms. Figure 1A il-
lustrates the typical clinical course of the RA in DA male
rats after injection of Mtb. The initial signs of arthritis
appeared around 10 to 13 days after the injection, mostly
as swelling of the metatarsophalangeal or ankle joints of
the hind paws. The inflammation progressed to the en-
tire hind paw (Figure 1B) and at a later stage, the joints
in the front paws also became inflamed. The inflamma-
tion’s peak appeared at around 20 days after Mtb-
injection; thereafter, the swelling progressively declined
and disappeared by about 40 days after Mtb-injection.
The body weight of treated animals started to decrease
six to seven days post-Mtb-injection. A loss of weight of
up to 18.5% could be observed. This loss of weight
stopped with the decrease of the inflammation. NoFigure 1 Model of arthritis in Dark Agouti rats. (A) Mean arthritic score
Mycobacterium tuberculosis H37 (Mtb, at the base of the tale) in non-treated
paws of non-treated (healthy) DA rats (i, iii) and treated (Mycobacterium tubapparent clinical symptoms occurred for the non-treated
animals. As expected for this group, a regular weight
gain was observed.Histological evaluation of the RA model
The arthritic effects of the RA model were analyzed on
histological joint sections stained with Hematoxylin and
Eosin at 20 days post-Mtb-injection. Severe signs of in-
flammation could be detected in treated rats (Figure 2B)
with an increased amount of infiltrated inflammatory
cells (such as lymphocytes and macrophages) while only
scarce proliferation was observed in non-treated rats
(Figure 2A). Immunohistochemical staining on joint sec-
tions was also performed in order to characterize TSPO
expressing cells. Specific antibodies directed against
CD68 and Iba 1 confirmed the significant increase of ac-
tivated macrophages in treated (RA) rats (Figure 3A, C)
compared to non-treated rats (Figure 3B, D). TSPO-
labeling on the RA rats’ joints slides (Figure 3E) was
mainly co-localized with CD68-labeling. Cell counting
showed that 23% of the cells present in the ankle were
CD68 positive. Among them, 95% expressed TSPO and
only about 5% were TSPO negative. In the inflamed
ankle, around 4% of the cells were visualized expressing
only the TSPO (CD68-). In non-treated animals, these
cell activations were not visible in joint slides and the
proportion of CD68 positive cell was less than 1%
(Figure 3F).and weight evolution at different times after injection of
(n = 6) and treated (n = 11) Dark Agouti (DA) rats. (B) Illustrations of
erculosis H37 Ra (Mtb)) rats (ii, iv) at 14 days. *P <0.05; **P <0.001.
A B
100µm 100µm
Figure 2 Histological characterization of the RA model in DA rats. Tissue slides from joints of non-treated rats (A) and joints from Mtb-
treated rats (B) were analyzed at 20 days post-injection using Hematoxylin and Eosin stained sections from ankle joints (hind paw). The
histological architecture shows synovial hyperplasia and infiltration of inflammatory cells. (Magnification x200).
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non-treated rats
The capacity to detect and quantify peripheral inflamma-
tion lesions in the hind paw of rats in vivo was evaluated
by microPET imaging using [18F]DPA-714. Figure 4A
shows an image of a coronal section in which increased
uptake of [18F]DPA-714 in ankles of Mtb-treated (RA) rat
(4A, i) compared to non-treated (control) rat (4A, ii) at
20 days. Both images are represented using the same color
scale. A sharp increase of the radiotracer’s uptake in the
ankles of the treated rat is clearly illustrated (indicated by
white arrows). A typical time-activity curve observed in
the hind paw of a treated rat at 20 days post-Mtb-
induction, scored 4 (clinical severity grade) is represented
in Figure 4B. As shown, the uptake of [18F]DPA-714 rap-
idly reached a maximum and steady value, only a few
minutes following the i.v. injection of the radiotracer and
remained stable throughout the 60-minute acquisition.
The mean [18F]DPA-714 uptake value in treated animals
was more than twice that of the non-treated animals.
Values reaching 0.52 ± 0.18 and 0.19 ± 0.09% ID/cc were
found for treated animals (n = 11 with a score ranging
from 5 to 16) and non-treated animals (n = 6), respectively
(Figure 4C). These results were statistically significant with
a P-value of 0.00008 (t-test).
In vivo specificity
To eliminate the possibility that [18F]DPA-714 uptake
was driven by unspecific processes, and also to evaluate
at the same time the specificity of this binding, animals
were injected 30 minutes post-[18F]DPA-714 administra-
tion, with a large excess (5 mg/kg of body weight) of
DPA-714 (unlabeled). Figure 5A permits us to compare
the same animal just before injection (5A, i) and 15 mi-
nutes after injection of unlabeled DPA-714 (5A, ii). An
important decrease of the signal in the ankles as well as
an increase of the background signal (illustrated by thehigher signal in the muscle) could be noticed following
the intravenous injection of non-labeled DPA-714. This
increase of background could mainly be explained by
the release of [18F]DPA-714 from the heart, lungs and
spleen, three organs characterized by a high level of
TSPO expression. Figure 5 illustrates the mean curve of
displacement carried out on four different animals with
similar grades of the disease. The mean radioactivity in
this group of animals is around 0.46 +/- 0.06% of ID/cc
just before the displacement challenge and decreased to
0.27 +/- 0.03% of ID/cc at 30 minutes after the injection
of unlabeled DPA-714. This variation corresponds to a
displacement around 45% of the initial signal present in
the ankles. During the same time, the mean value in the
muscle increased from 0.06 +/-0.01% ID/cc to 0.20 +/-
0.01% ID/cc corresponding to a variation around 300%.
Correlation between the uptake of [18F]DPA-714 and the
severity of the disease
To analyze the relation between the uptake of the radio-
tracer and the inflammatory status, the ID/cc and the
volume of the ankle were plotted as presented in
Figure 6. A linear regression, using the least square
method, gave a determination coefficient of R2 equal to
0.65 illustrating a good relation between the uptake of
this radiotracer and the severity (swelling) of the disease.
Discussion
The present study used a readily accessible, small
molecular weight, fluorine-18-labeled compound, coded
DPA-714, as the radiotracer for the inflammatory pro-
cesses. This TSPO radioligand has been largely used to
monitor neuroinflammation. The results published re-
cently in various articles illustrate the potential of [18F]
DPA-714 to provide quantitative information about the
expression of TSPO with correlation between the radio-
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Figure 3 TSPO expression in hind paws of RA rats is associated with activated macrophages. Slide tissues of treated (RA) (A and C) and
non-treated (control) rats (B and D) were stained with CD68 (red) or Iba1 (red) for activated macrophages. Nucleuses were colored with DAPI
(blue). Representative IHC staining of TSPO positives cells (green) from treated (RA) rats (E) and non-treated (control) rats (F) and the
colocalization with CD68 cells (red) are also shown. IHC, immunohistochemistry; RA, rheumatoid arthritis; TSPO, translocator protein.
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Western blot analysis [16,24]. In our inflammatory
model, biochemical analysis could not be easily per-
formed due to the presence of bones and cartilages. For
this reason we chose to illustrate the increase of TSPO
using IHC. This approach, done on fixed tissues, re-
quired a decalcification step to permit the slicing of the
articular tissues. These analyses were done on control,
mild and severe inflammatory grade permitting us to
visualize an increasing number of CD68 and TSPO posi-
tive cells (data not shown). The combination of both
[18F]DPA-714 PET imaging and IHC clearly illustrated
the increase of TSPO expression in the ankles of treated
rats in comparison to non-treated animals. IHC usingCD68 showed the important infiltration of white blood
cells, mainly macrophages, in the ankle. The CD68 posi-
tive cells represented around 25% of the cells counted on
tissue samples from inflamed ankles. Co-labeling using a
TSPO antibody showed that 95% of these CD68 marked
cells were also TSPO positive. TSPO is expressed in mito-
chondria whereas CD68 is mainly localized in cytoplasmic
granules. This non-overlap, adding to the counting error
incertitude, does not permit us to affirm that some CD68
positives cells are really TSPO negatives. These types of
cells (TSPO-; CD68+) represent less than one percent of
total cells counted in the different fields of view for this
quantitative approach. On the other hand, around 4% of




Figure 4 Enhanced uptake of [18F]DPA-714 in paws (ankle) of RA rats versus control using microPET. (A) Representative images in coronal
sections of the increased uptake of [18F]DPA-714 in the ankles of a Mtb-treated (RA) rat (A, i) compared to non-treated (control) rat (A, ii) at 20 days.
(B) Kinetics of [18F]DPA-714 uptake for non-treated and Mtb-treated (RA) rats. (C) Mean of [18F]DPA-714 uptake at 55 minutes for treated (RA) (n = 11)
versus non-treated (control) (n = 6) group. **P= 0.00008. Mtb, Mycobacterium tuberculosis H37 Ra; PET, positron emission tomography; RA, rheumatoid arthritis.
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lymphocytes or macrophages as suggested by the presence
of Iba1+/CD68- or MRP8+/CD68- cells.
Conventional radiography is nowadays considered as
the gold standard in RA imaging for the evaluation of
structural damages. The main limitation with this tech-
nique is that its sensitivity is considered to be low and
also that it is not able to assess the disease activity.
Recently, an international group of expert rheumatolo-
gists, radiologists and methodologists published some rec-






Figure 5 Displacement experiment by unlabeled DPA-714. (A) Visualiz
DPA-714 (A, i) and 15 minutes after injection of unlabeled DPA-714 (A, ii). (
by DPA-714. Arrow indicates time of displacement, 30 minutes after radiotrclinical management of rheumatoid arthritis [34]. They
compared the potential of different imaging techniques for
diagnosis of RA, detecting inflammation and damage, pre-
dicting outcome and response to treatment, monitoring
disease activity, progression and remission. These tech-
niques, conventional radiography, MRI, CT, dual emission
X-ray absorptiometry, digital X-ray radiogrammetry are
anatomical images based mainly on density alteration of
bones and cartilages. Two other techniques were included
in this comparative study, SPECT and PET imaging. These
two nuclear-based approaches mainly provide informationation of the same animal (treated) just before injection of unlabeled
B) Kinetics of [18F] DPA-714 uptake in the ankles and muscle, followed
acer injection.
Figure 6 Correlation between uptake and severity. For each
animal, the ID/cc and respective volume of the ankles were plotted.
The linear regression, using the least square method, gives a
determination coefficient R2 equal to 0.65.
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anatomical imaging. In arthritis, anatomical alterations of
bone, cartilage or at least severe stage tendon swelling,
represents a late stage of the disease with clinical symp-
toms illustrative of a long molecular process of inflamma-
tion. Concerning the diagnosis of RA, precocity has been
described as an important point to implement appropriate
therapeutics and thus limit structural alterations and de-
layed invalidity associated with this disease. Molecular im-
aging, such as TSPO PET imaging, represents a possibility
of following early events in the physiopathology of RA. It
has, therefore, been proposed that [11C]PK11195 PET im-
aging could be used for detecting early synovitis and for
monitoring the evolution of the disease during treatment
[7,10]. The present work, performed in a rat RA model,
demonstrates that [18F]DPA-714 can be used to image in-
flammation of joints non-invasively. The specificity of the
uptake was assessed here by intravenous injection of a
large amount of unlabeled DPA-714. This injection dis-
placed specific binding of [18F]DPA-714 by saturation of
TSPO binding site by a non-labelled compound. The phe-
nomena took place in an inflamed area but also in every
organ with a physiological high content of TSPO inducing
plasma release of a large quantity of [18F]DPA-714. This
effect is illustrated by the huge increase in an unspecific
signal quantified in the muscle with a variation from 0.06
to 0.20% of ID/cc (Figure 5B). In the inflamed ankles,
the displacement leads a decrease of the signal around
45%. After administration of unlabeled DPA-714, the
ankle-to-muscle ratio in these animals was around 1:4
while this ratio was 7:8 before administration. This value
illustrates that the signal quantified in the ankle after dis-
placement is largely due to background corresponding tofree [18F]DPA-714 (not bound to the TSPO 18kDa). In the
inflamed areas it has been shown that the vascular density
is also increased. This high vascular density can increase
the volume of blood in the considered area and participate
in the higher signal in comparison to normal ankles or
muscle use as the reference area. Local inflammation also
induces edema. Edematous areas are well known to
present high oncotic pressure inducing extravasation of
macromolecules. This phenomenon was not described for
small ligands, such as DPA-714, with a molecular weight
around 400 g/mol. This hypothesis is certainly not the ex-
planation concerning the remaining radioactivity present
in the ankle after displacement. The level of radiotracer
accumulation in the swollen hind paws correlates to the
thickness of the ankles, and is chosen as macroscopic cri-
teria for the severity of the disease (Figure 6). In this
graph, uptake results were expressed as density by number
of the receptors by volume unit here extrapolated as
Bequerel/cc corrected by the ID/cc. The fact that the in-
crease of ankle volume was linked to an increase of the
TSPO density (for example, [18F]DPA-714’s uptake) un-
derlines the relation between the severity of the disease
and the level of TSPO expression. This functional infor-
mation represents an important point concerning the abil-
ity of imaging techniques to evaluate disease activity, a
parameter simply not accessible using conventional ana-
tomical imaging approaches. Another criterion that repre-
sents a large interest for rheumatologists is the potential
of such non-invasive imaging tools and techniques to pre-
dict the evolution of the disease.
Conclusion
The results of the present work demonstrates that the use
of the TSPO-targeting PET-ligand [18F]DPA-714 is well-
adapted to the study of peripheral inflammation in an ex-
perimental rodent model of RA. [18F]DPA-714 PET im-
aging may provide new objective parameters to evaluate
the early stages of the disease and to determine disease ac-
tivity, also suggesting a strong potential of this technique
for clinical investigation of peripheral inflammation.
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